CARsgen Therapeutics, is focused on the development of CAR-T-based autologous immunotherapy utilizing its proprietary immunotherapy technology to fight against solid tumors.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/carsgen-therapeutics” connections=”true” suffix=””]

CARsgen is using chimeric antigen receptor T-cells (CAR-T) targeting the Epidermal Growth Factor Receptor (EGFR) for the treatment of glioblastoma (the most malignant type of brain cancer).